← back to search

William Pao

Vanderbilt University · US
Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics, HER2/EGFR in Cancer Research, and Lung Cancer Research Studies.
h-index
112
citations
66,793
works
668
NIH funding
primary concept
email

Recent publications

JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors
Science Signaling 2016cited by 63position: middledoi
Abstract PR16: Spatio-temporal heterogeneity in the tumor microenvironment influences the evolutionary dynamics of drug resistance
Cancer Research 2015cited by 0position: middledoi
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
JAMA 2014cited by 1,737position: middledoi
Anchored multiplex PCR for targeted next-generation sequencing
Nature Medicine 2014cited by 911position: middledoi
Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor–Resistant <i>EGFR</i> -Mutant Lung Cancer with and without T790M Mutations
Cancer Discovery 2014cited by 354position: lastdoi
FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer
Clinical Cancer Research 2014cited by 158position: middledoi
<scp>G</scp>enetic variants associated with longer telomere length are associated with increased lung cancer risk among never‐smoking women in Asia: a report from the female lung cancer consortium in Asia
International Journal of Cancer 2014cited by 90position: middledoi
Analysis of Major Known Driver Mutations and Prognosis in Resected Adenosquamous Lung Carcinomas
Journal of Thoracic Oncology 2014cited by 60position: middledoi
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers
Clinical Cancer Research 2013cited by 2,459position: middledoi
Characteristics of Lung Cancers Harboring <i>NRAS</i> Mutations
Clinical Cancer Research 2013cited by 142position: lastdoi
Afatinib—new therapy option for EGFR-mutant lung cancer
Nature Reviews Clinical Oncology 2013cited by 96position: lastdoi
A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC).
Journal of Clinical Oncology 2013cited by 60position: middledoi
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Cell 2012cited by 1,822position: middledoi
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Nature Genetics 2012cited by 1,417position: middledoi
<i>HER2</i> Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in <i>EGFR</i> -Mutant Lung Cancers That Lack the Second-Site <i>EGFR</i> T790M Mutation
Cancer Discovery 2012cited by 724position: lastdoi
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor <i>BRAF</i> gene mutations but lack mutations in <i>KRAS, NRAS,</i> or <i>MEK1</i>
Proceedings of the National Academy of Sciences 2012cited by 436position: lastdoi
Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia
Nature Genetics 2012cited by 351position: middledoi
Association of <i>KRAS</i> and <i>EGFR</i> mutations with survival in patients with advanced lung adenocarcinomas
Cancer 2012cited by 165position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Marc Ladanyi · Center for Cancer Research7 papers (2012–2016)Mark G. Kris · Kettering University6 papers (2012–2013)Maria E. Arcila · Molecular Oncology (United States)5 papers (2012–2016)Gregory J. Riely · Weill Cornell Medicine5 papers (2012–2014)Vincent A. Miller · Universidad San Carlos4 papers (2012–2014)Lecia V. Sequist · Harvard University3 papers (2012–2013)Kadoaki Ohashi · Hebron University3 papers (2012–2013)Elisa de Stanchina · European Molecular Biology Laboratory3 papers (2012–2016)Jeffrey A. Engelman · Novartis (Germany)3 papers (2012–2014)Juliann Chmielecki · AstraZeneca (United States)2 papers (2012–2014)Paul A. Bunn · University of Colorado Denver2 papers (2013–2013)Haichuan Hu · Sir Run Run Shaw Hospital2 papers (2014–2014)Yunjian Pan · Fudan University2 papers (2014–2014)Lei Shen · Yangtze Optical Electronic (China)2 papers (2014–2014)Yuan Li · Shihezi University2 papers (2014–2014)Yihua Sun · Fudan University2 papers (2014–2014)Xiaoyang Luo · Fudan University2 papers (2014–2014)Wilbur A. Franklin · University of Colorado Health2 papers (2013–2013)Teresa Morán · Universitat Autònoma de Barcelona2 papers (2012–2013)Hang Li · Fudan University2 papers (2014–2014)